Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome

Genes Chromosomes and Cancer

Volumn 50, Issue 8, 2011, Pages 606-618

  Huang, Jia ^a,b,g   Zhang, Lin ^a   Greshock, Joel ^b,h   Colligon, Theresa A ^b   Wang, Yan ^b,i   Ward, Renee ^b   Katsaros, Dionyssios ^c   Lassus, Heini ^d   Butzow, Ralf ^d   Godwin, Andrew K ^e   Testa, Joseph R ^f   Nathanson, Katherine L ^a   Gimotty, Phyllis A ^a   Coukos, George ^a,b   Weber, Barbara L ^b,i   Degenhardt, Yan ^b,h  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g China   (United States)

^h GLAXOSMITHKLINE   (United States)

ⁱ Novartis Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE 3CA; PHOSPHATIDYLINOSITOL 3 KINASE 3CB; PHOSPHATIDYLINOSITOL 3 KINASE 3R4; PROTEIN KINASE B; PROTEIN P110; SMALL INTERFERING RNA; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DOSAGE; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SALPINGOOOPHORECTOMY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TREATMENT OUTCOME;

APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 79958058359     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20883     Document Type: Article

References (38)

1. Bell DA. 2005. Origins and molecular pathology of ovarian cancer. Mod Pathol 18 (Suppl 2): S19-S32.
2. Dent P, Grant S, Fisher PB, Curiel DT. 2009. PI3K: A rational target for ovarian cancer therapy? Cancer Biol Ther 8: 27-30.
3. Elliott RL, Blobe GC. 2005. Role of transforming growth factor Beta in human cancer. J Clin Oncol 23: 2078-2093.
4. Fesik SW. 2005. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5: 876-885.
5. Gene Expression Omnibus (GEO) database. Available at
6. GenMAPP, gene map annotator and pathway profiler. Available at
7. Greshock J, Naylor TL, Margolin A, Diskin S, Cleaver SH, Futreal PA, deJong PJ, Zhao S, Liebman M, Weber BL. 2004. 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res 14: 179-187.
8. Greshock J, Nathanson K, Martin AM, Zhang L, Coukos G, Weber BL, Zaks TZ. 2007. Cancer cell lines as genetic models of their parent histology: Analyses based on array comparative genomic hybridization. Cancer Res 67: 3594-3600.
9. Ihle NT, Lemos R, Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. 2009. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69: 143-150.
10. Ingenuity Pathway Tools. Available at.
11. Johannsdottir HK, Jonsson G, Johannesdottir G, Agnarsson BA, Eerola H, Arason A, Heikkila P, Egilsson V, Olsson H, Johannsson OT, Nevanlinna H, Borg A, Barkardottir RB. 2006. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. Int J Cancer 119: 1052-1060.
12. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. 1998. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847.
13. Kops GJ, Weaver BA, Cleveland DW. 2005. On the road to cancer: Aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5: 773-785.
14. Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R. 2003. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 91: 504-512.
15. Lu Y, Wang H, Mills GB. 2003. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol 7: 205-228.
16. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, Park JK, Wang H, Peng Y, Jiang W, He TC. 2004. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 4: 653-671.
17. Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR. 2002. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 109: 141-149.
18. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J. 2001. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 28(5, Suppl 16): 125-141.
19. Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu VE, Wang TL, Shih Ie M. 2006. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 5: 779-785.
20. Nicosia SV, Bai W, Cheng JQ, Coppola D, Kruk PA. 2003. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am 17: 927-943.
21. Olshen AB, Venkatraman ES, Lucito R, Wigler M. 2004. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5: 557-572.
22. Olson JM, Hallahan AR. 2004. p38 MAP kinase: A convergence point in cancer therapy. Trends Mol Med 10: 125-129.
23. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ, Phillips WA. 2001. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61: 7426-7429.
24. Pinkel D, Albertson DG. 2005. Array comparative genomic hybridization and its applications in cancer. Nat Genet 37 (Suppl): S11-S17.
25. Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, Speed TP, Gorringe KL, Campbell IG. 2010. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One 5: e9983.
26. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
27. Sebolt-Leopold JS, Herrera R. 2004. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947.
28. Silva CM. 2004. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23: 8017-8023.
29. Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A, Zha J, Forrest WF, Nigro JM, Modrusan Z, Feuerstein BG, Phillips HS. 2007. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci USA 104: 3466-3471.
30. The Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
31. Vasilevskaya I, O'Dwyer PJ. 2003. Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist Update 6: 147-156.
32. Vivanco I, Sawyers CL. 2002. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2: 489-501.
33. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10: 789-799.
34. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. 2001. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98: 1176-1181.
35. Wilhelm M, Veltman JA, Olshen AB, Jain AN, Moore DH, Presti JC, Jr, Kovacs G, Waldman FM. 2002. Array-Based Comparative Genomic Hybridization for the Differential Diagnosis of Renal Cell Cancer. Cancer Res 62(4): 957-960.
36. Wilting SM, de Wilde J, Meijer CJ, Berkhof J, Yi Y, van Wieringen WN, Braakhuis BJ, Meijer GA, Ylstra B, Snijders PJ, Steenbergen RD. 2008. Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer 47: 890-905.
37. Zhang L, Huang J, Yang N, Greshock J, Liang S, Hasegawa K, Giannakakis A, Poulos N, O'Brien-Jenkins A, Katsaros D, Butzow R, Weber BL, Coukos G. 2007. Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 13(18, Part 1): 5314-5321.
38. Zhang X, Deng HX, Zhao X, Su D, Chen XC, Chen LJ, Wei YQ, Zhong Q, Li ZY, He X, Yi T. 2009. RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo. Oncology 77: 22-32.